The GlioGene® test is recommended for all patients with gliomas, regardless of type, grade or age.
This test is essential for the correct classification of tumours, which has important implications for the therapeutic approach of patients.
What is gliomaGliomas are a genetically, histologically and clinically heterogeneous group of tumours, located in the central nervous system (brain or spinal cord) or in the peripheral nervous system. They can grow from different types of neuroglial cells and their subcategorisation is essential for the differential diagnosis, management and treatment of patients.
Differential diagnosis: The examination can help in the proper differential diagnosis of gliomas to determine the exact type of tumor. This is important as different types of gliomas have different treatment approaches and prognosis.
Forecast: The test can help in the prognosis of the disease to determine the patient’s life expectancy.
Mutations identified in the IDH1,2 genes are associated with better disease prognosis and benefit from radiotherapy, while mutations in the BRAF gene have been associated with response to BRAF inhibitor therapy. Methylation of the MGMT gene promoter confers a survival advantage, particularly in older patients with high-grade gliomas. This can help patients and their families to understand the situation better and make appropriate plans.
Selection of the appropriate treatment: Testing can help in choosing the appropriate treatment, as certain biomarkers correlate with response to specific treatments. Simultaneous co-deletion of chromosomal regions 1p & 19q gives a favourable prognosis of the disease and is predictive of response to alkylating systemic therapy.
The test uses modern molecular techniques such as NGS, FISH and Real-time PCR.
These technologies allow the simultaneous analysis of molecular biomarkers which, in combination with histopathological findings, provide a comprehensive picture for the better clinical management of each patient.
What types of cancer does it cover?
What is the turnaround time for my results?
10 working days
What type of sample is required for the test?
For the analysis of Gliogene® we need the paraffin cube from the tumor or alternatively uncolored paraffin sections coated on slides (air-dried, not oven-dried). More specifically, we need 4 sections of 3μm and 6 sections of 10μm.
Does any public/private insurance cover the test?
For information on test cost coverage you should contact your personal insurance or our company.
How do I make the payment for the test?
The Customer Service Department will provide you with a unique e-banking payment code, or payment can be made by card or bank transfer.
How can I send my sample?
Genekor is responsible for all necessary procedures for the receipt and return of your sample. To arrange sample collection and return, please contact us.
How will I get my results?
Your results will be shared with your doctor via a secure network and to you via e-mail with a secure unique code provided by customer service.
Why do I have to sign the consent form?
GeneKor I.A.E. is certified according to ISO 9001:2015 (ref. 041150049) and according to ELOT ISO/IEC 27001:2013 (ref. 048190009) by TUV NORD HELLAS, which requires the written consent of each patient for the use of his/her genetic material for testing.
It is also necessary to follow data protection regulations.
Our Customer Service Team is committed to answering your questions about the services offered by Genekor. If you are interested in any of the tests offered by Genekor, please contact us directly.
To complete the test, you are required to complete and send the Consent form that you will find here
For more scientific information please contact: scientific.support@genekor.com
*Download the promotional brochure here.